Olivier Huillard, Co-CEO at Areltys, Medical Oncologist at AP-HP, shared a post on LinkedIn:
“Last week, I had the opportunity to take part in the DayOne – Healthtech Innovation Showcase 2025 in Basel, the closing event of the DayOne Accelerator, hosted at Roche.
As a medical oncologist and co-founder of Areltys, this event resonated strongly with the space where my work sits today: at the intersection of clinical practice, research, and digital innovation.
The discussions throughout the Showcase highlighted a shared challenge we all recognize from different angles: how to translate real science and technological innovation into concrete, usable solutions that fit clinical reality and genuinely improve patient access to care.
At Areltys, we focus on this challenge through Radioligand Therapy (RLT): supporting healthcare teams by simplifying complex pathways and helping innovative treatments reach patients more efficiently and more responsibly.
What stood out at DayOne was the quality of the dialogue between startups, pharma leaders and investors grounded, demanding, and focused on long-term impact rather than hype.
Thank you to the DayOne – Healthtech Innovation team (Cécile Tardy-Srinivasan, Pascal Clisson, Ursula Costa, Yana Yoncheva, Caoimhe Vallely-Gilroy) and Basel Area Business & Innovation for building such a thoughtful ecosystem, and congratulations to all the founders of the 2025 cohort for the depth and ambition of their work (C. Light Technologies, Inc., EVIIVE AG, Harmonic Discovery, Lemna Bio, Menken Trials, Nanolynx Biologics, Navis Bio, Octozi, OmniScience, Parithera, Virtuosis AI, ZuriEV).
Looking forward to continuing these conversations across disciplines, sectors, and borders.”
More posts featuring Olivier Huillard on OncoDaily.